Avoid use in patients with moderate or severe hepatic impairment (Child-Pugh B or C).
Skip to main content
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Caplyta (Intra-Cellular Therapies)
- INDICATIONS: Treatment of schizophrenia in adults.
- CLASS: Antipsychotic, Antipsychotic, atypical / antipsychotic, second-generation
- HALF-LIFE: ~18 hours
- FDA APPROVAL DATE: 12/20/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amprenavir, Aprepitant, Armodafinil, Carbamazepine, Ciprofloxacin, Clarithromycin, Cyclosporine, CYP3A4 inducers, Diltiazem, Efavirenz, Erythromycin, Etravirine, Fluconazole, Fluvoxamine, Grapefruit Juice, Itraconazole, Modafinil, moderate or strong CYP3A4 inhibitors, Nafcillin, Nefazodone, Nelfinavir, Phenytoin, Pioglitazone, Prednisone, Probenecid, Rifampin, Ritonavir, St John's Wort, UGT inhibitors, Valproic Acid, Verapamil, Voriconazole - PREGNANCY: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Breastfeeding is not recommended.
- See adverse reactions attributed to class:
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED
PSYCHOSIS
ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. LUMATEPERONE IS NOT APPROVED FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
